Telmisartan in comorbid patients with obesity and arterial hypertension
https://doi.org/10.37586/2686-8636-1-2026-124-130
Abstract
Against the backdrop of the rising global prevalence of overweight and the established link between obesity, activation of the renin-angiotensin-aldosterone system (RAAS), and hypertension, selecting an antihypertensive agent capable of targeting the common pathogenetic pathways of these conditions is critical for comorbid patients. This article analyzes the therapeutic potential of telmisartan, a highly selective angiotensin II receptor blocker with unique pharmacokinetic properties. Due to its pronounced lipophilicity, the drug ensures effective blockade of tissue RAAS, which accounts for its high organoprotective activity. Particular attention is given to the specific mechanism of telmisartan as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ). This property allows the drug to function as a metabolic modulator: promoting adipose tissue redistribution, reducing visceral fat area, lowering triglyceride levels, and improving insulin sensitivity. The presented data lead to the conclusion that the use of telmisartan is a pathogenetically justified and rational choice for treating comorbid patients with concomitant hypertension and obesity as well as cardiovascular-renal-hepatic-metabolic syndrome, enabling the achievement of target blood pressure levels while simultaneously correcting metabolic disturbances.
About the Authors
V. D. Zakiev
Russian Gerontological Clinical and Research Center, Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
Yu. V. Kotovskaya
Russian Gerontological Clinical and Research Center, Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990– 2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025 ; 405 (10481) : 813–838. DOI: 10.1016/S0140-6736(25)00355-1.
2. Zhernakova Yu. V., Zheleznova E. A., Chazova I. E., et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study — ESSE-RF. Terapevticheskii arkhiv. 2018 ; 90 (10) : 14–22. (In Russ.)]. DOI: 10.26442/terarkh201890104-22.
3. Withrow D., Alter D. A. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011 ; 12 (2) : 131–141. DOI: 10.1111/j.1467-789X.2009.00712.x.
4. Garrison R. J., Kannel W. B., Stokes J. 3rd, Castelli W. P. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987 ; 16 (2) : 235–251. DOI: 10.1016/0091-7435(87)90087-9.
5. Salvetti A., Brogi G., Di Legge V., Bernini G. P. The inter-relationship between insulin resistance and hypertension. Drugs. 1993 ; 46 Suppl 2 : 149–159. DOI: 10.2165/00003495-199300462-00024.
6. Tomás E., Lin Y. S., Dagher Z., et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci. 2002 ; 967 : 43–51. DOI: 10.1111/j.1749-6632.2002.tb04262.x.
7. Bjornstad P., Eckel R. H. Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review. Curr Diab Rep. 2018 ; 18 (12) : 127. DOI: 10.1007/s11892-018-1101-6.
8. DeFronzo R. A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010 ; 53 (7) : 1270–1287. DOI: 10.1007/s00125-010-1684-1.
9. Reddy K. J., Singh M., Bangit J. R., Batsell R. R. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. J Cardiovasc Med (Hagerstown). 2010 ; 11 (9) : 633–647. DOI: 10.2459/JCM.0b013e328333645a.
10. Fazio S., Mercurio V., Tibullo L., et al. Insulin resistance / hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated. Front Cardiovasc Med. 2024 ; 11 : 1380506. DOI: 10.3389/fcvm.2024.1380506. Erratum in: Front Cardiovasc Med. 2025 ; 12 : 1720220. DOI: 10.3389/fcvm.2025.1720220.
11. Shlyakhto E. V., Nedogoda S. V., Babenko A. Yu., et al. Concept of an interdisciplinary consensus document on cardiovascular-renal-hepatic-metabolic syndrome. Russian Journal of Cardiology. 2025 ; 30 (1S) : 6533 (In Russ.)]. DOI: 10.15829/1560-4071-2025-6533.
12. Velloso L. A., Folli F., Sun X. J., et al. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A. 1996 ; 93 (22) : 12490–12495. DOI: 10.1073/pnas.93.22.12490.
13. de Kloet A. D., Krause E. G., Woods S. C. The renin angiotensin system and the metabolic syndrome. Physiol Behav. 2010 ; 100 (5) : 525–534. DOI: 10.1016/j.physbeh.2010.03.018.
14. Nakagami H., Morishita R. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. Curr Vasc Pharmacol. 2011; 9 (2) : 162–166. DOI: 10.2174/157016111794519291.
15. De Gasparo M. Les récepteurs A. T. (1 ) et AT(2 ) de l'angiotensine II: l'essentiel [AT(1) and AT(2) angiotensin II receptors: key features]. Drugs. 2002 ; 62 Spec No 1 : 1–10.
16. Zaiken K., Cheng J. W. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Ther. 2011 ; 33 (11) : 1577– 1589. DOI: 10.1016/j.clinthera.2011.10.007.
17. Ojima M., Igata H., Tanaka M., et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011 ; 336 (3) : 801–808. DOI: 10.1124/jpet.110.176636.
18. Liu X., Chen C., Smith B. J. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008 ; 325 (2) : 349–356. DOI: 10.1124/jpet.107.130294.
19. Michel M. C., Foster C., Brunner H. R., Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013 ; 65 : 809– 848. DOI: 10.1124/pr.112.007278.
20. Zakiev V. D., Kotovskaya Yu. V., Tkacheva O. N. Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review. Terapevticheskii Arkhiv. 2023 ; 95 (9) : 810–817. (In Russ.)]. DOI: 10.26442/00403660.2023.09.202423.
21. Telzap®. Instrukciya po primeneniyu [Electronic resource]. Reestr OHLP i LV EAEHS. (In Russ.)]. Режим доступа: https://lk.regmed.ru/Register/EAEU_SmPC, свободный.
22. Parati G., Schumacher H., Bilo G., Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010 ; 28 (11) : 2177–2183. DOI: 10.1097/HJH.0b013e32833e1150.
23. Ragot S., Ezzaher A., Meunier A., et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens. 2002 ; 16 (12) : 865–873. DOI: 10.1038/sj.jhh.1001494.
24. Williams B., Gosse P., Lowe L., et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006 ; 24 : 193–200. DOI: 10.1097/01.hjh.0000194364.11516.ab.
25. Lacourcière Y., Neutel J. M., Davidai G., et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006 ; 19 (1) : 104–112. DOI: 10.1016/j.amjhyper.2005.10.001.
26. Gosse P., Schumacher H. Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies. Hypertens Res. 2014 ; 37 (2) : 151–157. DOI: 10.1038/hr.2013.121.
27. Neutel J. M., Frishman W. H., Oparil S., et al. Comparison of telmisartan with lisinopril in patients with mild-tomoderate hypertension. Am J Ther. 1999 ; 6 (3) : 161–166. DOI: 10.1097/00045391-199905000-00007.
28. Takagi H., Niwa M., Mizuno Y., et al; All-Literature Investigation of Cardiovascular Evidence Group. A metaanalysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. Hypertens Res. 2013 ; 36 (11) : 959–966. DOI: 10.1038/hr.2013.78.
29. Neutel J., Smith D. H. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: metaanalysis of a clinical database. J Clin Hypertens (Greenwich). 2003 ; 5 (1) : 58–63. DOI: 10.1111/j.1524-6175.2003.01612.x.
30. Takagi H., Niwa M., Mizuno Y., et al; ALICE (AllLiterature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction. Hypertens Res. 2013 ; 36 (7) : 627–633. DOI: 10.1038/hr.2012.233.
31. Wang J. G., Zhang M., Feng Y. Q., et al. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2021 ; 23 (5) : 901–914. DOI: 10.1111/jch.14227.
32. Kumari K., Toppo M. S., Majhi L., Kumar A. Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis. J Family Med Prim Care. 2022 ; 11 (10) : 6227– 6235. DOI: 10.4103/jfmpc.jfmpc_787_22.
33. ONTARGET Investigators; Yusuf S., Teo K. K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15) : 1547–1559. DOI: 10.1056/NEJMoa0801317.
34. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S., Sleight P., et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 ; 342 (3) : 145–153. DOI: 10.1056/NEJM200001203420301. Erratum in: 2000 ; 342 (18) : 1376. Erratum in: N Engl J Med 2000 ; 342 (10) : 748.
35. Yusuf S., Teo K. K., Anderson C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 ; 372 : 1174–1183. DOI: 10.1016/S0140-6736(08)61242-8.
36. Yusuf S., Diener H. C., Sacco R. L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 ; 359 (12) : 1225–1237. DOI: 10.1056/NEJMoa0804593.
37. Ayza M. A., Zewdie K. A., Tesfaye B. A., et al. Anti-Diabetic Effect of Telmisartan Through its Partial PPARγAgonistic Activity. Diabetes Metab Syndr Obes. 2020 ; 13 : 3627–3635. DOI: 10.2147/DMSO.S265399.
38. Haraguchi T., Iwasaki K., Takasaki K., et al. Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia. Brain Res. 2010 ; 1353 : 125–132. DOI: 10.1016/j.brainres.2010.07.017.
39. Amano Y., Yamaguchi T., Ohno K., et al. Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens Res. 2012 ; 35 (7) : 715–719. DOI: 10.1038/hr.2012.17.
40. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res. 2002 ; 43 (2) : 177–186.
41. Choi S. S., Park J., Choi J. H. Revisiting PPARγ as a target for the treatment of metabolic disorders. BMB Rep. 2014 ; 47 (11) : 599–608. DOI: 10.5483/bmbrep.2014.47.11.174.
42. Wakino S., Law R. E., Hsueh W. A. Vascular protective effects by activation of nuclear receptor PPARgamma. J Diabetes Complications. 2002 ; 16 (1) : 46–49. DOI: 10.1016/s1056-8727(01)00197-0.
43. Medina-Gomez G., Gray S. L., Yetukuri L., et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007 ; 3 (4) : e64. DOI: 10.1371/journal.pgen.0030064.
44. Choi S. H., Chung S. S., Park K. S. Rehighlighting the action of PPARγ in treating metabolic diseases. F1000Res. 2018 ; 7 : F1000 Faculty Rev-1127. DOI: 10.12688/f1000research.14136.1.
45. Doktorova M, Zwarts I, Zutphen TV, et al. Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia. Sci Rep. 2017 ; 7 (1) : 846. DOI: 10.1038/s41598-017-00889-z.
46. Rosen E. D., Spiegelman B. M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001 ; 276 (41) : 37731–37734. DOI: 10.1074/jbc.R100034200.
47. Galzerano D., Capogrosso C., Di Michele S., et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 ; 6 : 113–133. DOI: 10.2147/vhrm.s7857.
48. Clasen R., Schupp M., Foryst-Ludwig A., et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005 ; 46 (1) : 137–143. DOI: 10.1161/01.HYP.0000168046.19884.6a.
49. Min L. J., Mogi M., Shudou M., et al. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension. 2012 ; 59 (5) : 1079–1088. DOI: 10.1161/HYPERTENSIONAHA.112.192401.
50. Ushijima K., Takuma M., Ando H., et al. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. Eur J Pharmacol. 2013 ; 698 (1-3) : 505–510. DOI: 10.1016/j.ejphar.2012.11.022.
51. Naguib Y. M., Samaka R. M., Rizk M. S., et al. Countering adipose tissue dysfunction could underlie the superiority of telmisartan in the treatment of obesityrelated hypertension. Cardiovasc Diabetol. 2021 ; 20 (1) : 70. DOI: 10.1186/s12933-021-01259-w.
52. Murakami K., Wada J., Ogawa D., et al. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diab Vasc Dis Res. 2013 ; 10 (1) : 93–96. DOI: 10.1177/1479164112444640. Erratum in: Diab Vasc Dis Res. 2013 ; 10 (6) : 554.
53. Shimabukuro M., Tanaka H., Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007 ; 25 (4) : 841–848. DOI: 10.1097/HJH.0b013e3280287a83.
54. Choi G. J., Kim H. M., Kang H., Kim J. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2016 ; 32 (7) : 1303–1309. DOI: 10.1185/03007995.2016.1171204.
55. Kakuma T., Gotoh K., Masaki T., et al. Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome. Obes Res Clin Pract. 2010 ; 4 (2) : e83–e162. DOI: 10.1016/j.orcp.2009.12.003.
56. Suksomboon N., Poolsup N., Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther. 2012 ; 37 (3) : 319–327. DOI: 10.1111/j.1365-2710.2011.01295.x.
57. Takagi H., Umemoto T.; All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens. 2014 ; 8 (8) : 578–592. DOI: 10.1016/j.jash.2014.05.006.
58. Takagi H., Niwa M., Mizuno Y., et al. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013 ; 7 (3) : 229–235. DOI: 10.1016/j.jash.2013.02.006.
59. Takagi H., Yamamoto H., Iwata K., et al. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol. 2013 ; 167 (4) : 1443–1449. DOI: 10.1016/j.ijcard.2012.04.058.
60. Makino H., Haneda M., Babazono T., et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res. 2008 ; 31 (4) : 657–664. DOI: 10.1291/hypres.31.657.
61. Deneka I. Е., Rodionov A. V., Fomin V. V. The use of telmisartan in patients with refractory arterial hypertension and obesity. Cardiovascular Therapy and Prevention. 2019 ; 18 (1) : 73–81 (In Russ.)]. DOI: 10.15829/1728-8800-2019-1-73-81.
62. Kobalava Zh. D., Konradi A. O., Nedogoda S. V., et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024 ; 29 (9) : 6117 (In Russ.)]. DOI: 10.15829/1560-4071-2024-6117.
63. Ageev F. T., Smirnova M. D. Clinical Efficacy and Tolerability of Antihypertensive Therapy with Single Pill Combinations of Telmisartan in Patients with Arterial Hypertension in Clinical Practice According to the ON TIME Observational Study. Rational Pharmacotherapy in Cardiology. 2022 ; 18 (6) : 638–647. (In Russ.)]. DOI: 10.20996/1819-6446-2022-12-01.
Review
For citations:
Zakiev V.D., Kotovskaya Yu.V. Telmisartan in comorbid patients with obesity and arterial hypertension. Russian Journal of Geriatric Medicine. 2026;(1):124-130. (In Russ.) https://doi.org/10.37586/2686-8636-1-2026-124-130
Views:
205
JATS XML
Email this article 